RESEARCH · BPC-157 + TB-500 · MUSCULOSKELETAL MODELS
BPC-157 and Thymosin Beta-4 in Tendon, Ligament and Muscle Injury Models: Study Designs, Endpoints and Limits
PurixLab’s BPC-157 + TB-500 10mg is a research vial combining a pentadecapeptide and a thymosin beta-4 fragment. Our earlier articles cover the preclinical evidence and the human data gap, proposed molecular mechanisms, gastrointestinal models and ischaemia-reperfusion models. This article maps the musculoskeletal injury models in detail: which tendon, ligament, muscle and bone injuries were created, what was measured, and where independent data diverge. The material is supplied for laboratory research use only, and nothing here describes effects of any PurixLab product.
A model family built mostly by one group
A 2019 review of tendon, ligament and skeletal-muscle studies noted that the work had been done mainly in small rodent models, that only a handful of research groups had studied the peptide in depth, and that efficacy had not been confirmed in humans [1]. A 2025 systematic review from an orthopaedic perspective included 36 studies, of which 35 were preclinical [2]. The models below share a template: a surgical or crush injury in rats, systemic or local administration starting shortly after injury, and serial functional, biomechanical and histological assessment.
Tendon: transection and detachment
In the first tendon model, the rat Achilles tendon was transected 5 mm proximal to its calcaneal insertion and assessed on days 1, 4, 7, 10 and 14. Treated animals had higher load to failure and Young’s modulus, better Achilles functional index values and better collagen formation. In culture, the peptide had no effect of its own on tendocyte growth but opposed the growth-inhibiting aldehyde 4-hydroxynonenal [3]. A tendon-to-bone detachment model, followed for up to 21 days, added a corticosteroid arm: methylprednisolone consistently worsened healing, and BPC-157 reduced that worsening [4]. In seventy-two rats studied over days 1 to 4, before collagen healing begins, the peptide lowered myeloperoxidase activity and raised a vascular index, whereas methylprednisolone also lowered myeloperoxidase but reduced new vessel formation and did not improve early function [5].
Explant and cell work from a different laboratory showed faster outgrowth of tendon fibroblasts from explants, better survival under hydrogen peroxide stress and increased migration, without a direct effect on proliferation [6], together with increased growth hormone receptor expression [7].
Ligament
After transection of the rat medial collateral ligament, followed for 90 days, the peptide given intraperitoneally, in drinking water or as a thin topical cream layer was associated with functional, biomechanical, macroscopic and histological improvements [8]. Full-length thymosin beta-4 has one comparable study: after the same injury, a fibrin sealant containing the protein placed in the ligament gap produced more evenly spaced fibre bundles, larger collagen fibril diameters and better mechanical properties at 4 weeks [9].
Muscle, junctions and bone
In a complete quadriceps transection that rats cannot compensate for, the group reported improvements over a 72-day period in load of failure, walking recovery, desmin staining and myofibril diameter [10]. In a gastrocnemius crush model, systemic or local cream application was associated with less haematoma and oedema and lower creatine kinase, lactate dehydrogenase and transaminase activity [11], and a follow-up reported that the peptide counteracted the impairment caused by systemic methylprednisolone [12]. The same models showed no direct angiogenic effect of BPC-157 in cell culture but modulated VEGF, CD34 and factor VIII staining in healing tissue [13].
Later work moved to junctions: separation of the quadriceps tendon from the muscle, assessed at 7, 14, 28 and 42 days with eNOS, COX-2 and oxidative-stress measurements [14], and detachment of the quadriceps from bone, followed for up to 90 days with ultrasound and magnetic resonance imaging [15]. The oldest model is a 0.8 cm segmental radius defect in rabbits, where the effect was compared with bone marrow and autologous cortical bone grafts [16].
Thymosin beta-4 in muscle: a mixed record
Thymosin beta-4 and thymosin beta-10 mRNA rose in early regenerating muscle fibres after injury in mice, and thymosin beta-4 and its sulphoxide attracted C2C12 and primary myoblasts [17]. In dystrophin-deficient mdx mice treated for 6 months, the protein increased the number of regenerating fibres but did not significantly improve grip strength, cardiac function or fibrosis [18]. A proteomics study identified thymosin beta-4 as the most upregulated protein secreted by contracting myotubes and found it raised in the plasma of exercising humans, yet treating mice with it did not enhance muscle regeneration [19]. These studies used the full-length protein; TB-500 preparations analysed by doping laboratories contained an N-acetylated 17-23 fragment [20].
The combination study
The only published study testing both peptides together comes from a different research group. Thirty-two rats with repaired Achilles tendons were divided into four groups of eight and examined at 4 weeks. Load to failure was higher with each peptide than with controls but significant only for TB-500; total Bonar scores were significantly lower with TB-500, and total Movin scores with TB-500 and the combination. BPC-157 alone showed numerically lower scores without significance, and the combination did not add benefit over either agent alone [21].
Human data and open questions
A 2026 systematic review found three human studies with 30 participants in total (a retrospective knee-pain series, a pilot study in interstitial cystitis and a two-person safety study), all of poor methodological quality, and rated the certainty of evidence very low [22]. A 2026 sports-medicine review stresses that rigorous human safety data for unapproved peptides are scarce [23].
- Replication. Most in vivo tendon, ligament and muscle results come from one network of authors; the independent combination study found a smaller BPC-157 effect [1,21].
- Follow-up. Observation periods ran from days to 90 days, so long-term remodelling is largely unmeasured [3,8].
- Identity. TB-500 is not the same molecule as full-length thymosin beta-4 [20].
- Humans. There are no controlled human trials of musculoskeletal endpoints [22].
BPC-157 + TB-500 10mg at PurixLab
BPC-157 + TB-500 10mg: a labelled lyophilized research vial with BPC-157 5mg + TB-500 5mg per vial (10mg total), C$89 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/bpc-157-tb-500-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PubMed 30915550 · doi:10.1007/s00441-019-03016-8
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PubMed 40756949 · PMC12313605 · doi:10.1177/15563316251355551
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-83. PubMed 14554208 · doi:10.1016/S0736-0266(03)00110-4
- Krivic A, Anic T, Seiwerth S, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-9. PubMed 16583442 · doi:10.1002/jor.20096
- Krivic A, Majerovic M, Jelic I, et al. Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. Inflamm Res. 2008;57(5):205-10. PubMed 18594781 · doi:10.1007/s00011-007-7056-8
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. PubMed 21030672 · doi:10.1152/japplphysiol.00945.2010
- Chang CH, Tsai WC, Hsu YH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-77. PubMed 25415472 · PMC6271067 · doi:10.3390/molecules191119066
- Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-61. PubMed 20225319 · doi:10.1002/jor.21107
- Xu B, Yang M, Li Z, et al. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regul Pept. 2013;184:1-5. PubMed 23523891 · doi:10.1016/j.regpep.2013.03.026
- Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res. 2006;24(5):1109-17. PubMed 16609979 · doi:10.1002/jor.20089
- Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716-25. PubMed 18668315 · doi:10.1007/s00595-007-3706-2
- Pevec D, Novinscak T, Brcic L, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010;16(3):BR81-88. PubMed 20190676
- Brcic L, Brcic I, Staresinic M, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009;60 Suppl 7:191-6. PubMed 20388964
- Japjec M, Horvat Pavlov K, Petrovic A, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines. 2021;9(11):1547. PubMed 34829776 · PMC8615275 · doi:10.3390/biomedicines9111547
- Matek D, Matek I, Staresinic E, et al. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025;17(1):119. PubMed 39861766 · PMC11768438 · doi:10.3390/pharmaceutics17010119
- Sebecić B, Nikolić V, Sikirić P, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation. Bone. 1999;24(3):195-202. PubMed 10071911 · doi:10.1016/s8756-3282(98)00180-x
- Tokura Y, Nakayama Y, Fukada S, et al. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. J Biochem. 2011;149(1):43-8. PubMed 20880960 · doi:10.1093/jb/mvq115
- Spurney CF, Cha HJ, Sali A, et al. Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. PLoS One. 2010;5(1):e8976. PubMed 20126456 · PMC2813286 · doi:10.1371/journal.pone.0008976
- Gonzalez-Franquesa A, Stocks B, Borg ML, et al. Discovery of thymosin β4 as a human exerkine and growth factor. Am J Physiol Cell Physiol. 2021;321(5):C770-C778. PubMed 34495765 · doi:10.1152/ajpcell.00263.2021
- Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PubMed 22962027 · doi:10.1002/dta.1402
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PubMed 42542926 · doi:10.52312/jdrs.2026.2951
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). PubMed 42885452 · doi:10.52628/92.3.15837
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PubMed 41966639 · doi:10.1007/s40279-026-02437-0